Valiant Laboratories to acquire 1.01% stake in AMPYR Renewable Energy for up to ₹70 Lakh
Valiant Laboratories will invest up to ₹70 Lakhs to acquire a stake in AMPYR Renewable Energy Resources Twelve A Private Limited. The acquisition aims to secure solar power for its Tarapur plant under a group captive arrangement. The company will hold up to 1.01% equity and 3.60% preference shares.
The investment amount of ₹70 Lakhs is relatively small compared to the company's overall operations, thus having a low financial impact.
The company is making a strategic investment to secure renewable energy, which is a positive development for its sustainability and operational efficiency.
Valiant Laboratories Limited has announced its decision to acquire a significant stake in AMPYR Renewable Energy Resources Twelve A Private Limited. The Board of Directors, in a meeting held on September 17, 2026, approved the proposed acquisition and holding of shares in AMPYR.
The aggregate consideration for this investment will not exceed ₹70,00,000 (Rupees Seventy Lakhs only). This strategic move is aimed at availing renewable energy under a group captive open access arrangement, which will help the company procure solar power for its Tarapur plant.
AMPYR Renewable Energy Resources Twelve A Private Limited, incorporated on November 1, 2023, is a subsidiary of AMPYR India Asset Holdings Two Pte. Ltd., Singapore. The entity is involved in the renewable energy sector, specifically in the development and generation of solar power. As of March 31, 2026, AMPYR reported a net worth of ₹9.99 Crore and a turnover of ₹23.26 Crore. The acquisition does not involve related parties and is expected to be completed within 12 months from the date of approval, upon execution of definitive agreements.
Upon completion, Valiant Laboratories proposes to acquire and hold up to 1.01% of the Equity Share Capital and up to 3.60% of the Compulsorily Convertible Preference Shares of AMPYR, aligning with the group captive arrangement requirements under the Electricity Act, 2003. The investment will not result in any change of control or management of AMPYR.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.